Centers for Advanced Research


APDA Centers for Advanced Research received nearly $700,000 in funding in 2014. The Centers served more than 26,000 patients and supported the following: research trainees; fellowship programs; published peer review manuscripts and provided pilot data for NIH grants. The Centers facilitate optimum research at the forefront of Parkinson's disease in the following areas: inflammation in PD; DBS programs; functional surgery; epidemiological studies; genetics, clinical trials, biomarkers for PD; exercise in PD; ultrasound projects; heritability, the role of TG2; atypical parkinsonism; non-motor symptoms; alpha-synuclein; PD self-management; preclinical assessment of investigational therapies and L-dopa studies.



David G. Standaert, MD, Ph.D, Director
University of Alabama at Birmingham, School of Medicine

APDA funding supports:
  • Inflammation in PD
  • 5,054 patient visits per year
  • Deep Brain Stimulation (DBS) Program
  • 24 peer-reviewed manuscripts


UCLA David Geffen School of Medicine
Marie-Francoise Chesselet, MD, Ph.D,Director
UCLA David Geffen School of Medicine

APDA funding supports:
  • Epidemiological studies in humans
  • Genetic & molecular studies in model organisms
  • Preclinical assessment of investigational therapies
  • Approximately 1,000 patient visits per year


Emory University School of Medicine
Mahlon R. DeLong, MD, Director
Emory University School of Medicine

APDA funding supports:
  • Functional surgery
  • Research trainees
  • Two day intensive evaluation of PD patients
  • Approximately 10,000 total patients seen each year


Boston University School of Medicine
Marie Hélène Saint-Hilaire, MD, FRCP (C), Director
Boston University School of Medicine

APDA funding supports:
  • Observational study of Social Self-Management in PD
  • Study of Tai Chi in PD
  • Active clinical trials program- Approximately 3,500 PD patient visits this year


Washington University School of Medicine
Joel S. Perlmutter, MD, Director
Washington University School of Medicine

APDA funding supports:
  • Provided pilot data for six currently funded NIH RO1 grants
  • Biomarkers for PD & cognitive impairment occurrence
  • Exercise, emphasizing gait and balance
  • More than 4,000 PD patient visits


Rutgers-Robert Wood Johnson Medical School
Lawrence I. Golbe, MD, Director
Rutgers-Robert Wood Johnson Medical School

APDA funding supports:
  • Neuroprotective activity of a non-caffeine component of coffee
  • The role of TG2 in the pathologic aggregation of alpha-synuclein
  • L-dopa induced dyskinesia Atypical parkinsonism, progressive supranuclear palsy
  • 999 patient visits per year


University of Pittsburgh Medical Center
J. Timothy Greenamyre, MD, PhD, Director
University of Pittsburgh Medical Center

APDA funding supports:
  • Fellowship program in movement
  • DBS offered intraoperative MRI guided
  • Non-motor symptoms study
  • Therapeutic alpha-synuclein knockdown study
  • 1,000 patient visits per year


Madaline B. Harrison, MD, Director
University of Virginia Health System

APDA funding supports:
  • MR guided focused ultrasound projects
  • Genetics and characterization of neuropsychiatric disorders in Parkinson's Disease
  • Heritability of motor and non-motor symptoms in PD
  • Approximately 857 patient visits per year